Skip to main content
main-content

01.01.2012 | Original Article | Ausgabe 1/2012

Supportive Care in Cancer 1/2012

Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid

Zeitschrift:
Supportive Care in Cancer > Ausgabe 1/2012
Autoren:
Sachin R. Shah, Gary W. Jean, Sidney V. Keisner, Sarah M. Gressett Ussery, Jonathan E. Dowell
Wichtige Hinweise
Poster presentation at the Hematology/Oncology Pharmacist Association (HOPA) 2010 Annual Meeting Trainee Research Poster Session, March 25, 2010. Abstract accepted for online publication only in conjunction with the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Abstract

Purpose

The purpose of this study was to evaluate the incidence of acute renal failure (ARF) in patients with mild to moderate renal dysfunction, receiving renally adjusted zoledronic acid (ZA) and compare it to patients with normal baseline renal function, receiving standard-dose ZA.

Methods

This was a retrospective study of patients receiving ZA for the treatment of bone metastasis due to cancer. Patients were divided into two groups: (1) normal group with baseline creatinine clearance (CrCl) of greater than 60 mL/min and standard ZA dose; (2) impaired group with baseline CrCl of 30–60 mL/min and renally adjusted ZA dose. Primary endpoint of ARF was defined as an increase in serum creatinine (SCr) of 0.5 mg/dL or 1.0 mg/dL from a baseline SCr of <1.4 mg/dL or ≥1.4 mg/dL, respectively.

Results

In total, 1,472 evaluable doses of ZA were given to 220 patients. Of these, 184 patients were in the normal group and 36 patients in the impaired group. There were 38 patients (20.7%) who developed ARF in the normal group versus 7 patients (19.4%) in the impaired group. There was no difference in the mean time to the incidence of ARF at 6.1 months in both groups. Incidence of ARF based on CrCl (≥25% decline in CrCl) was similar between groups (39.1% vs. 41.7%; p = 0.78).

Conclusion

The incidence of ARF is similar between patients in the normal group and impaired group when the ZA dose is renally adjusted.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med zum Sonderpreis bestellen!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

Supportive Care in Cancer 1/2012 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.


 

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise